At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 129 enrolled
Drug / intervention
CXA-101 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Double-blind, Randomized, Phase 2 Study to Compare the Safety and Efficacy of Intravenous CXA-101 and Intravenous Ceftazidime in Complicated Urinary Tract Infection, Including Pyelonephritis
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)·interventional·Posted Jun 16, 2009·Updated Oct 18, 2018
In Brief
A Phase 2 clinical trial evaluating CXA-101 and Ceftazidime for Complicated Urinary Tract Infection. Completed, enrolled 129 participants across 21 sites in 3 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of intravenous CXA 101 and comparator in complicated urinary tract infection
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsComplicated Urinary Tract Infection
CountriesGermany, Poland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2009
Enrollment StartJun 2009
Primary CompletionFeb 2010
Study CompletionMar 2010
TodayJul 2026
First PostedJun 16, 2009
Enrollment StartJun 30, 2009
Primary CompletionFeb 25, 2010
Study CompletionMar 11, 2010
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 17.0 years ago
Interventions
CXA-101drug
intravenous
Ceftazidimedrug
intravenous